WCN26-3177 BASELINE CHARACTERISTICS OF PARTICIPANTS IN BAXASIA: PHASE 3 STUDY OF THE ALDOSTERONE SYNTHASE INHIBITOR BAXDROSTAT IN ADULTS WITH UNCONTROLLED OR RESISTANT HYPERTENSION PRIMARILY FROM ASIA

Read full text Summarise with VIRAT
Authors: Hirotaka Shibata, Michel Azizi, Jenifer Michelle Brown, Wei Duan, Jamie P. Dwyer, John M. Flack, Erika S.W. Jones, Lei Liu, Shira Perl, Ji-Guang Wang, Junjie Wu, Bryan Williams
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In the Phase 3 BaxHTN study in adults with uncontrolled (uHTN) or resistant (rHTN) hypertension, the selective aldosterone synthase inhibitor, baxdrostat, at 1 and 2 mg/day in addition to background therapy, lowered seated office systolic blood pressure (SBP) by 8.7 and 9.8 mmHg, respectively, vs placebo at 12 weeks. BaxAsia (NCT06344104) has a similar randomised, double-blind design comparing the efficacy and safety of baxdrostat vs placebo in hypertensive patients primarily from Asia. Here, we present the baseline characteristics of participants included in BaxAsia.

Fields of Study & Subjects

Hormonal Regulation and Hypertension Blood Pressure and Hypertension Studies Renin-Angiotensin System Studies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105027–105027
Publication date
25 March 2026
Language
EN